Status:
COMPLETED
Effect of Injectable Anticoagulants on Research for a Circulating Lupus-type Anticoagulant
Lead Sponsor:
University Hospital, Clermont-Ferrand
Conditions:
Antiphospholipid Syndrome
Anticoagulant Drugs
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
The aim is to assess the effect of injectable anticoagulants (unfractionated heparin (UFH), low molecular weight heparins (LMWH), fondaparinux, danaparoid, argatroban) on lupus anticoagulant testing a...
Detailed Description
Citrated whole blood was collected from subjects with positive lupus anticoagulant (LA) testing and from subjects with negative LA testing. Injectable anticoagulants were prepared in demineralized wat...
Eligibility Criteria
Inclusion
- For all subjects:
- Adult male or female subject.
- In capacity to give informed consent to participate in the research.
- Affiliated to a Social Security system.
- For the LA- group:
- Without a previous thrombosis and considered healthy on the basis of the interview and clinical examination.
- Without coagulation disease
- For the LA+ group:
- \- Notion of the presence of lupus anticoagulant (according to ISTH criteria) and whose last test was positive.
Exclusion
- For all subjects:
- Medical history considered by the investigator to be incompatible with the trial
- Refused participation
- Recent administration of oral or injectable anticoagulants
- INR \> 1.5
- Pregnant women, nursing mothers
- Guardianship, curatorship, deprived of liberty, safeguard of justice
Key Trial Info
Start Date :
June 2 2022
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
May 21 2024
Estimated Enrollment :
188 Patients enrolled
Trial Details
Trial ID
NCT05416190
Start Date
June 2 2022
End Date
May 21 2024
Last Update
June 21 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
CHU clermont-ferrand
Clermont-Ferrand, France